An Insider Richard Aldrich Unloaded 31236 shares of Concert Pharmaceuticals, Inc. (CNCE); Last Week Pioneer Power Solutions, Inc. (PPSI) Analysts

Among 3 analysts covering Pioneer Power Solutions (NASDAQ:PPSI), 2 have Buy rating, 1 Sell and 0 Hold. Therefore 67% are positive. Pioneer Power Solutions had 5 analyst reports since October 16, 2015 according to SRatingsIntel. On Friday, October 16 the stock rating was downgraded by TheStreet to “Sell”. On Thursday, October 29 the stock rating was maintained by TH Capital with “Buy”. Roth Capital maintained the shares of PPSI in report on Sunday, August 13 with “Buy” rating. The rating was maintained by Roth Capital with “Buy” on Thursday, October 29. See Pioneer Power Solutions, Inc. (NASDAQ:PPSI) latest ratings:

13/08/2017 Broker: Roth Capital Rating: Buy New Target: $8.0000 Maintain

The director of Concert Pharmaceuticals Inc and corporation’s insider Richard Aldrich unloaded 31,236 shares of the Massachusetts-based company based on the market stock price per share of $19.1 of a share. The reported shares are valued at approx. $597,833 USD. The date was 18/11/2018 when Richard reported the deal, and it was unveiled in a report with the SEC, accessible online on this website. Mr. Richard at the moment has rights to 421,326 shares, accounting for 1.85% of the company’s total market capitalization.

The stock decreased 1.15% or $0.23 during the last trading session, reaching $19.71. About 508,795 shares traded or 9.34% up from the average. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has risen 18.70% since January 18, 2017 and is uptrending. It has outperformed by 2.00% the S&P500.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company has market cap of $448.85 million. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. It has a 5.07 P/E ratio. The company??s clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer??s disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis.

Among 9 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Concert Pharmaceuticals has $34.0 highest and $20.0 lowest target. $27’s average target is 36.99% above currents $19.71 stock price. Concert Pharmaceuticals had 22 analyst reports since August 12, 2015 according to SRatingsIntel. On Wednesday, August 9 the stock rating was maintained by H.C. Wainwright with “Buy”. Stifel Nicolaus initiated the stock with “Buy” rating in Friday, July 1 report. The firm has “Buy” rating given on Monday, September 18 by H.C. Wainwright. As per Friday, January 12, the company rating was maintained by Stifel Nicolaus. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) earned “Buy” rating by H.C. Wainwright on Friday, October 20. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) earned “Buy” rating by UBS on Tuesday, December 19. The firm earned “Buy” rating on Monday, November 6 by Mizuho. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) earned “Buy” rating by Stifel Nicolaus on Thursday, October 19. The firm has “Neutral” rating given on Friday, January 12 by Mizuho. The firm has “Buy” rating given on Monday, June 12 by Aegis Capital.

Analysts await Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) to report earnings on March, 5. They expect $-0.18 earnings per share, up 66.67% or $0.36 from last year’s $-0.54 per share. After $-0.70 actual earnings per share reported by Concert Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -74.29% EPS growth.

Investors sentiment increased to 1.18 in 2017 Q3. Its up 0.05, from 1.13 in 2017Q2. It is positive, as 13 investors sold Concert Pharmaceuticals, Inc. shares while 20 reduced holdings. 17 funds opened positions while 22 raised stakes. 14.57 million shares or 5.31% more from 13.83 million shares in 2017Q2 were reported. California State Teachers Retirement System, California-based fund reported 28,469 shares. Ny State Common Retirement Fund owns 16,200 shares. Sg Americas Secs Limited Liability Company has invested 0% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Manchester Cap Management Limited Liability Corporation has invested 0.05% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). 127,724 were reported by Bancorporation Of New York Mellon Corporation. Swiss Natl Bank holds 27,792 shares. Princeton Capital Mngmt stated it has 14,607 shares. Ingalls Snyder Ltd Liability Co reported 1.21 million shares. Mufg Americas Hldgs holds 0% or 255 shares in its portfolio. Franklin owns 687,000 shares or 0% of their US portfolio. Pdt Prtnrs Limited Com reported 59,393 shares. Fincl Bank Of America De owns 48,068 shares. Lyon Street Ltd Co reported 463,064 shares. State Street has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). 13,691 are held by Credit Suisse Ag.

Since September 14, 2017, it had 1 buy, and 1 insider sale for $5.21 million activity. $50,785 worth of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) was sold by Lynch Ryan on Thursday, September 14. On Thursday, October 19 BVF PARTNERS L P/IL bought $5.26 million worth of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) or 331,916 shares.

Investors sentiment increased to 1.25 in 2017 Q3. Its up 0.65, from 0.6 in 2017Q2. It is positive, as 2 investors sold Pioneer Power Solutions, Inc. shares while 2 reduced holdings. 2 funds opened positions while 3 raised stakes. 1.75 million shares or 3.02% more from 1.70 million shares in 2017Q2 were reported. Kennedy Inc invested 0.06% of its portfolio in Pioneer Power Solutions, Inc. (NASDAQ:PPSI). Vanguard Gp has invested 0% in Pioneer Power Solutions, Inc. (NASDAQ:PPSI). Blackrock stated it has 0% in Pioneer Power Solutions, Inc. (NASDAQ:PPSI). 7 were accumulated by Royal National Bank Of Canada. North Star Inv Management Corporation accumulated 413,607 shares. Fifth Third National Bank holds 0% or 1,000 shares in its portfolio. Heartland Advsr Inc holds 0.17% or 350,500 shares in its portfolio. First Wilshire Secs Management has invested 0.64% of its portfolio in Pioneer Power Solutions, Inc. (NASDAQ:PPSI). Morgan Stanley invested in 110 shares. Tower Research Cap Llc (Trc) holds 0% of its portfolio in Pioneer Power Solutions, Inc. (NASDAQ:PPSI) for 81 shares. 17,600 were accumulated by California Public Employees Retirement. Macquarie Gru Ltd holds 8,275 shares. 137,800 are held by Perritt Cap Management.